You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEstradiol
Accession NumberDB00783  (APRD00311)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionGenerally refers to the 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. In humans, it is produced primarily by the cyclic ovaries and the placenta. It is also produced by the adipose tissue of men and postmenopausal women. The 17-alpha-isomer of estradiol binds weakly to estrogen receptors (receptors, estrogen) and exhibits little estrogenic activity in estrogen-responsive tissues. Various isomers can be synthesized. [PubChem]
Structure
Thumb
Synonyms
(17beta)-Estra-1,3,5(10)-triene-3,17-diol
17beta Oestradiol
17beta-Estra-1,3,5(10)-triene-3,17-diol
17beta-Oestradiol
Benzhormovarine
beta-Estradiol
cis-Estradiol
Dihydrofollicular hormone
Dihydrofolliculin
Dihydrotheelin
Dihydroxyestrin
Estradiol
Estradiol
Estradiol
Estradiol-17beta
Estradiolum
Femestral
Lio-Oid
External Identifiers
  • E3A
  • NSC 17590
  • SQ 16150
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AloraPatch.025 mg/dTransdermalActavis Pharma, Inc.2002-04-05Not applicableUs
AloraPatch.05 mg/dTransdermalActavis Pharma, Inc.1996-12-20Not applicableUs
AloraPatch.075 mg/dTransdermalActavis Pharma, Inc.1996-12-20Not applicableUs
AloraPatch.1 mg/dTransdermalActavis Pharma, Inc.1996-12-20Not applicableUs
ClimaraPatch.025 mg/dTransdermalBayer Health Care Pharmaceuticals Inc.1999-03-05Not applicableUs
ClimaraPatch.05 mg/dTransdermalBayer Health Care Pharmaceuticals Inc.1994-12-22Not applicableUs
ClimaraPatch.0375 mg/dTransdermalBayer Health Care Pharmaceuticals Inc.2003-05-27Not applicableUs
ClimaraPatch.1 mg/dTransdermalBayer Health Care Pharmaceuticals Inc.1994-12-22Not applicableUs
ClimaraPatch.06 mg/dTransdermalBayer Health Care Pharmaceuticals Inc.2008-01-03Not applicableUs
ClimaraPatch.075 mg/dTransdermalBayer Health Care Pharmaceuticals Inc.1998-03-23Not applicableUs
Climara 100Patch7.6 mgTransdermalBayer Inc1997-12-01Not applicableCanada
Climara 25Patch2 mgTransdermalBayer Inc2004-03-12Not applicableCanada
Climara 50Patch3.8 mgTransdermalBayer Inc1997-12-01Not applicableCanada
Climara 75Patch5.7 mgTransdermalBayer Inc2004-03-12Not applicableCanada
DelestrogenInjection10 mg/mLIntramuscularPar Pharmaceutical Inc.2007-11-01Not applicableUs
DelestrogenInjection20 mg/mLIntramuscularPar Pharmaceutical Inc.2007-11-01Not applicableUs
DelestrogenInjection40 mg/mLIntramuscularPar Pharmaceutical Inc.2007-11-01Not applicableUs
Delestrogen Inj 10mg/mlLiquid10 mgIntramuscularTheramed Corporation1955-12-312008-03-03Canada
DivigelGel0.1 %TransdermalTeva Canada Limited2015-04-13Not applicableCanada
DivigelGel1 mg/gTopicalUpsher Smith Laboratories, Inc.2011-02-28Not applicableUs
DivigelGel.25 mg/gTopicalVertical Pharmaceuticals, LLC2014-10-27Not applicableUs
DivigelGel0.1 %TransdermalTeva Canada Limited2015-04-13Not applicableCanada
DivigelGel.5 mg/gTopicalVertical Pharmaceuticals, LLC2014-10-27Not applicableUs
DivigelGel.25 mg/gTopicalUpsher Smith Laboratories, Inc.2011-02-28Not applicableUs
DivigelGel0.1 %TransdermalTeva Canada Limited2015-04-13Not applicableCanada
DivigelGel0.1 %TransdermalTeva Canada Limited2012-09-272015-04-23Canada
DivigelGel1 mg/gTopicalVertical Pharmaceuticals, LLC2014-10-27Not applicableUs
DivigelGel.5 mg/gTopicalUpsher Smith Laboratories, Inc.2011-02-28Not applicableUs
DivigelGel1 mg/gTopicalPhysicians Total Care, Inc.2009-08-04Not applicableUs
ElestrinGel, metered.52 mg/gTopicalMEDA Pharmaceuticals2014-06-02Not applicableUs
ElestrinGel, metered.52 mg/gTopicalMEDA Pharmaceuticals2014-06-02Not applicableUs
ElestrinGel.6 mg/gTransdermalJazz Pharmaceuticals Commercial Corp.2007-06-01Not applicableUs
ElestrinGel.6 mg/gTransdermalJazz Pharmaceuticals Commercial Corp.2007-06-01Not applicableUs
EstraceTablet1 mgOralAcerus Pharmaceuticals Corporation1995-12-31Not applicableCanada
EstraceTablet0.5 mgOralAcerus Pharmaceuticals Corporation1997-07-10Not applicableCanada
EstraceTablet2 mgOralAcerus Pharmaceuticals Corporation1995-12-31Not applicableCanada
Estrace Tab 1mgTablet1 mgOralBristol Labs Division Of Bristol Myers Squibb1976-12-311999-01-07Canada
Estrace Tab 2mgTablet2 mgOralBristol Labs Division Of Bristol Myers Squibb1976-12-311998-04-07Canada
Estraderm-100Patch, extended release8 mgTransdermalNovartis Pharmaceuticals Canada Inc1987-12-312013-01-08Canada
Estraderm-25Patch, extended release2 mgTransdermalNovartis Pharmaceuticals Canada Inc1987-12-312012-10-25Canada
Estraderm-50Patch, extended release4 mgTransdermalNovartis Pharmaceuticals Canada Inc1987-12-312010-05-10Canada
EstradiolTablet0.5 mgOralAcerus Pharmaceuticals CorporationNot applicableNot applicableCanada
EstradiolPatch, extended release.075 mg/dTransdermalSandoz Inc2014-12-22Not applicableUs
EstradiolPatch, extended release.025 mg/dTransdermalSandoz Inc2014-12-22Not applicableUs
EstradiolTablet1 mgOralAcerus Pharmaceuticals CorporationNot applicableNot applicableCanada
EstradiolPatch, extended release.1 mg/dTransdermalSandoz Inc2014-12-22Not applicableUs
EstradiolPatch, extended release.0375 mg/dTransdermalSandoz Inc2014-12-22Not applicableUs
EstradiolTablet2 mgOralAcerus Pharmaceuticals CorporationNot applicableNot applicableCanada
EstradiolPatch, extended release.05 mg/dTransdermalSandoz Inc2014-12-22Not applicableUs
Estradiol Transdermal SystemPatch.0375 mg/dTransdermalAlvogen, Inc.2011-12-20Not applicableUs
Estradiol Transdermal SystemPatch.1 mg/dTransdermalAlvogen, Inc.2011-12-19Not applicableUs
Estradiol Transdermal SystemPatch.05 mg/dTransdermalAlvogen, Inc.2011-12-20Not applicableUs
Estradiol Transdermal SystemPatch.06 mg/dTransdermalAlvogen, Inc.2011-12-20Not applicableUs
Estradiol Transdermal SystemPatch.025 mg/dTransdermalAlvogen, Inc.2011-12-20Not applicableUs
Estradiol Transdermal SystemPatch.075 mg/dTransdermalAlvogen, Inc.2011-12-20Not applicableUs
Estradiol ValerateInjection20 mg/mLIntramuscularJHP Pharmaceuticals, LLC2012-06-01Not applicableUs
Estradiol ValerateInjection40 mg/mLIntramuscularJHP Pharmaceuticals, LLC2012-06-01Not applicableUs
Estradiol ValerateInjection10 mg/mLIntramuscularJHP Pharmaceuticals, LLC2012-06-01Not applicableUs
Estradot 100Patch1.56 mgTransdermalNovartis Pharmaceuticals Canada Inc2001-09-05Not applicableCanada
Estradot 25Patch0.39 mgTransdermalNovartis Pharmaceuticals Canada Inc2002-10-03Not applicableCanada
Estradot 37.5Patch0.585 mgTransdermalNovartis Pharmaceuticals Canada Inc2001-09-05Not applicableCanada
Estradot 50Patch0.780 mgTransdermalNovartis Pharmaceuticals Canada Inc2001-09-05Not applicableCanada
Estradot 75Patch1.17 mgTransdermalNovartis Pharmaceuticals Canada Inc2001-09-05Not applicableCanada
EstringRing2 mg/1VaginalPharmacia And Upjohn Company Llc1996-04-26Not applicableUs
EstringRing2 mgVaginalPfizer Canada Inc1995-12-31Not applicableCanada
EstringRing2 mg/1VaginalPhysicians Total Care, Inc.2006-02-27Not applicableUs
EstringRing2 mg/1VaginalU.S. Pharmaceuticals1996-04-26Not applicableUs
EstrogelGel, metered.75 mg/1.25gTransdermalASCEND Therapeutics US, LLC2004-02-09Not applicableUs
EstrogelGel0.06 %TransdermalMerck Canada Inc1998-11-16Not applicableCanada
EstrogelGel, metered.75 mg/1.25gTransdermalASCEND Therapeutics US, LLC2004-02-09Not applicableUs
EvamistSpray1.53 mg/1TransdermalPaddock Laboratories, LLC2015-04-11Not applicableUs
EvamistSpray, metered1.53 mg/1TransdermalPhysicians Total Care, Inc.2010-08-23Not applicableUs
EvamistSpray, metered1.53 mg/1TransdermalTher Rx Corporation2009-07-08Not applicableUs
FemringRing.05 mg/dVaginalAllergan, Inc.2016-05-02Not applicableUs
FemringRing.05 mg/dVaginalWarner Chilcott (US), LLC2003-07-01Not applicableUs
FemringRing.1 mg/dVaginalAllergan, Inc.2016-05-02Not applicableUs
FemringRing.1 mg/24[USP'U]VaginalPhysicians Total Care, Inc.2009-05-04Not applicableUs
FemringRing.1 mg/dVaginalWarner Chilcott (US), LLC2003-07-01Not applicableUs
Lupin-estradiolTablet2 mgOralLupin Pharma Canada Limited2016-02-29Not applicableCanada
Lupin-estradiolTablet0.5 mgOralLupin Pharma Canada Limited2016-02-29Not applicableCanada
Lupin-estradiolTablet1 mgOralLupin Pharma Canada Limited2016-02-29Not applicableCanada
MenostarPatch14 ug/dTransdermalBayer Health Care Pharmaceuticals Inc.2004-06-08Not applicableUs
MinivelleFilm, extended release.1 mg/dTransdermalNOVEN THERAPEUTICS, LLC2012-12-20Not applicableUs
MinivelleFilm, extended release.075 mg/dTransdermalNOVEN THERAPEUTICS, LLC2012-12-20Not applicableUs
MinivelleFilm, extended release.025 mg/dTransdermalNOVEN THERAPEUTICS, LLC2012-12-20Not applicableUs
MinivelleFilm, extended release.0375 mg/dTransdermalNOVEN THERAPEUTICS, LLC2012-12-20Not applicableUs
MinivelleFilm, extended release.05 mg/dTransdermalNOVEN THERAPEUTICS, LLC2012-12-20Not applicableUs
Neo-diol Inj 20mg/mlLiquid20 mgIntramuscularNeolab Inc1982-12-312003-07-29Canada
OesclimPatch10 mgTransdermalFournier Pharma Inc1998-09-292002-07-12Canada
OesclimPatch7.5 mgTransdermalSearchlight Pharma Inc2015-05-29Not applicableCanada
OesclimPatch15 mgTransdermalSearchlight Pharma Inc2015-05-29Not applicableCanada
OesclimPatch5 mgTransdermalSearchlight Pharma Inc2002-03-22Not applicableCanada
OesclimPatch5 mgTransdermalFournier Pharma Inc1998-09-292002-07-12Canada
OesclimPatch20 mgTransdermalSearchlight Pharma Inc2015-05-29Not applicableCanada
OesclimPatch10 mgTransdermalSearchlight Pharma Inc2002-03-21Not applicableCanada
PMS-estradiol Valerate Inj 10mg/mlLiquid10 mgIntramuscularPharmascience Inc1989-12-312016-10-28Canada
Sandoz Estradiol Derm 100Patch8 mgTransdermalSandoz Canada Incorporated2003-04-24Not applicableCanada
Sandoz Estradiol Derm 50Patch4 mgTransdermalSandoz Canada Incorporated2003-04-24Not applicableCanada
Sandoz Estradiol Derm 75Patch6 mgTransdermalSandoz Canada Incorporated2003-04-24Not applicableCanada
VagifemTablet, film coated10 ug/1VaginalPhysicians Total Care, Inc.2010-09-24Not applicableUs
VagifemTablet25 mcgVaginalNovo Nordisk Canada Inc2002-05-082014-07-28Canada
VagifemInsert10 ug/1VaginalNovo Nordisk2010-01-11Not applicableUs
Vagifem 10Tablet10 mcgVaginalNovo Nordisk Canada Inc2010-04-28Not applicableCanada
Vivelle 100mcgPatch8.66 mgTransdermalNovartis Pharmaceuticals Canada Inc1996-12-312003-12-03Canada
Vivelle 37.5mcgPatch3.28 mgTransdermalNovartis Pharmaceuticals Canada Inc1996-12-312003-12-03Canada
Vivelle 50mcgPatch4.33 mgTransdermalNovartis Pharmaceuticals Canada Inc1996-12-312008-11-21Canada
Vivelle 75mcgPatch6.56 mgTransdermalNovartis Pharmaceuticals Canada Inc1996-12-312003-12-03Canada
Vivelle DotPatch, extended release.0375 mg/dTransdermalPhysicians Total Care, Inc.2003-09-23Not applicableUs
Vivelle DotPatch, extended release.05 mg/dTransdermalPhysicians Total Care, Inc.2003-06-10Not applicableUs
Vivelle DotPatch, extended release.075 mg/dTransdermalPhysicians Total Care, Inc.2003-06-10Not applicableUs
Vivelle DotPatch, extended release.1 mg/dTransdermalPhysicians Total Care, Inc.2003-06-10Not applicableUs
Vivelle-dotPatch, extended release.1 mg/dTransdermalNovartis Pharmaceuticals Corporation1999-01-08Not applicableUs
Vivelle-dotPatch, extended release.0375 mg/dTransdermalNovartis Pharmaceuticals Corporation1999-01-08Not applicableUs
Vivelle-dotPatch, extended release.025 mg/dTransdermalNovartis Pharmaceuticals Corporation1999-01-08Not applicableUs
Vivelle-dotPatch, extended release.05 mg/dTransdermalNovartis Pharmaceuticals Corporation1999-01-08Not applicableUs
Vivelle-dotPatch, extended release.075 mg/dTransdermalNovartis Pharmaceuticals Corporation1999-01-08Not applicableUs
YuvafemTablet10 ug/1VaginalAmneal Pharmaceuticals Llc2016-02-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Depo-estradiolInjection5 mg/mLIntramuscularPhysicians Total Care, Inc.1998-10-16Not applicableUs
Depo-estradiolInjection5 mg/mLIntramuscularPharmacia And Upjohn Company Llc1979-08-15Not applicableUs
EstraceTablet2 mg/1OralWarner Chilcott (US), LLC2011-12-26Not applicableUs
EstraceCream.1 mg/gVaginalAllergan, Inc.2001-07-01Not applicableUs
EstraceTablet.5 mg/1OralWarner Chilcott (US), LLC2011-12-26Not applicableUs
EstraceTablet1 mg/1OralWarner Chilcott (US), LLC2011-12-26Not applicableUs
EstradiolTablet1 mg/1OralProficient Rx LP1996-03-14Not applicableUs
EstradiolPatch.0375 mg/dTransdermalMylan Pharmaceuticals Inc.2014-12-19Not applicableUs
EstradiolTablet1 mg/1OralA S Medication Solutions1997-10-28Not applicableUs
EstradiolPatch.025 mg/dTransdermalMylan Pharmaceuticals Inc.2005-03-28Not applicableUs
EstradiolInsert10 ug/1VaginalAmneal Pharmaceuticals of New York, LLC2015-06-07Not applicableUs
EstradiolTablet2 mg/1OralBlenheim Pharmacal, Inc.2012-03-05Not applicableUs
EstradiolTablet2 mg/1OralAv Pak2014-02-12Not applicableUs
EstradiolTablet1 mg/1OralCardinal Health2009-12-17Not applicableUs
EstradiolTablet1 mg/1OralAvera Mc Kennan Hospital2015-06-23Not applicableUs
EstradiolTablet1 mg/1OralA S Medication Solutions1996-03-14Not applicableUs
EstradiolTablet.5 mg/1OralKAISER FOUNDATION HOSPITALS2010-10-07Not applicableUs
EstradiolTablet1 mg/1OralA S Medication Solutions1999-06-17Not applicableUs
EstradiolTablet1 mg/1OralAidarex Pharmaceuticals LLC1997-10-28Not applicableUs
EstradiolTablet2 mg/1OralRebel Distributors Corp1996-03-14Not applicableUs
EstradiolTablet.5 mg/1OralPhysicians Total Care, Inc.2003-06-09Not applicableUs
EstradiolTablet.5 mg/1Oralbryant ranch prepack1996-03-14Not applicableUs
EstradiolTablet2 mg/1OralTeva Pharmaceuticals Usa, Inc.1997-10-28Not applicableUs
EstradiolTablet.5 mg/1OralAvera Mc Kennan Hospital2015-10-29Not applicableUs
EstradiolPatch.0375 mg/dTransdermalMylan Pharmaceuticals Inc.2006-08-10Not applicableUs
EstradiolTablet.5 mg/1OralMylan Pharmaceuticals Inc.1999-06-17Not applicableUs
EstradiolTablet.5 mg/1OralGolden State Medical Supply, Inc.2016-08-16Not applicableUs
EstradiolTablet2 mg/1OralWatson Laboratories, Inc.1996-03-14Not applicableUs
EstradiolTablet1 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-12Not applicableUs
EstradiolTablet2 mg/1OralGolden State Medical Supply, Inc.2014-11-26Not applicableUs
EstradiolPatch.1 mg/dTransdermalMylan Pharmaceuticals Inc.2014-12-19Not applicableUs
EstradiolTablet.5 mg/1OralMayne Pharma Inc.2016-08-03Not applicableUs
EstradiolTablet.5 mg/1Oralbryant ranch prepack1996-03-14Not applicableUs
EstradiolPatch.025 mg/dTransdermalMylan Pharmaceuticals Inc.2014-12-19Not applicableUs
EstradiolTablet2 mg/1OralA S Medication Solutions1997-10-28Not applicableUs
EstradiolPatch.05 mg/dTransdermalMylan Pharmaceuticals Inc.2000-02-24Not applicableUs
EstradiolTablet.5 mg/1OralStat Rx USA1997-10-22Not applicableUs
EstradiolTablet1 mg/1OralPd Rx Pharmaceuticals, Inc.2009-12-17Not applicableUs
EstradiolTablet1 mg/1OralAvera Mc Kennan Hospital2015-07-14Not applicableUs
EstradiolTablet2 mg/1OralA S Medication Solutions1996-03-14Not applicableUs
EstradiolTablet1 mg/1OralKAISER FOUNDATION HOSPITALS2010-10-20Not applicableUs
EstradiolTablet2 mg/1OralAidarex Pharmaceuticals LLC1997-10-28Not applicableUs
EstradiolTablet2 mg/1OralA S Medication Solutions1997-10-28Not applicableUs
EstradiolPatch.06 mg/dTransdermalMylan Pharmaceuticals Inc.2006-08-10Not applicableUs
EstradiolTablet.5 mg/1OralHeritage Pharmaceuticals Inc2010-11-05Not applicableUs
EstradiolPatch.97 mg/48[USP'U]TransdermalPhysicians Total Care, Inc.2003-06-14Not applicableUs
EstradiolTablet1 mg/1OralReady Meds1996-03-14Not applicableUs
EstradiolTablet.5 mg/1OralTeva Pharmaceuticals Usa, Inc.1997-10-28Not applicableUs
EstradiolPatch.075 mg/dTransdermalMylan Pharmaceuticals Inc.2014-12-19Not applicableUs
EstradiolTablet1 mg/1OralMayne Pharma Inc.2016-08-03Not applicableUs
EstradiolTablet1 mg/1OralMylan Pharmaceuticals Inc.1999-06-17Not applicableUs
EstradiolTablet1 mg/1OralGolden State Medical Supply, Inc.2016-08-16Not applicableUs
EstradiolTablet.5 mg/1OralWatson Laboratories, Inc.1996-03-14Not applicableUs
EstradiolTablet.5 mg/1OralAv Pak2014-02-12Not applicableUs
EstradiolTablet.5 mg/1OralDIRECT RX2015-11-25Not applicableUs
EstradiolTablet1 mg/1Oralbryant ranch prepack1996-03-14Not applicableUs
EstradiolTablet1 mg/1OralNu Care Pharmaceuticals, Inc1997-10-28Not applicableUs
EstradiolPatch.075 mg/dTransdermalMylan Pharmaceuticals Inc.2005-03-28Not applicableUs
EstradiolTablet1 mg/1OralSTAT Rx USA LLC1996-03-14Not applicableUs
EstradiolTablet1 mg/1OralPhysicians Total Care, Inc.2000-09-18Not applicableUs
EstradiolTablet2 mg/1OralPd Rx Pharmaceuticals, Inc.1996-03-14Not applicableUs
EstradiolTablet.5 mg/1OralGolden State Medical Supply, Inc.2014-11-26Not applicableUs
EstradiolTablet.5 mg/1OralPd Rx Pharmaceuticals, Inc.1996-03-14Not applicableUs
EstradiolTablet.5 mg/1OralA S Medication Solutions1996-03-14Not applicableUs
EstradiolTablet1 mg/1OralKAISER FOUNDATION HOSPITALS2012-09-12Not applicableUs
EstradiolTablet.5 mg/1OralPd Rx Pharmaceuticals, Inc.2009-12-17Not applicableUs
EstradiolTablet1 mg/1OralPd Rx Pharmaceuticals, Inc.2016-08-03Not applicableUs
EstradiolTablet.5 mg/1OralA S Medication Solutions1997-10-28Not applicableUs
EstradiolTablet1 mg/1OralHeritage Pharmaceuticals Inc2010-11-05Not applicableUs
EstradiolPatch1.46 mg/48[USP'U]TransdermalPhysicians Total Care, Inc.2003-06-09Not applicableUs
EstradiolTablet2 mg/1OralReady Meds1996-03-14Not applicableUs
EstradiolPatch.05 mg/dTransdermalMylan Pharmaceuticals Inc.2014-12-19Not applicableUs
EstradiolTablet2 mg/1OralMayne Pharma Inc.2016-08-03Not applicableUs
EstradiolTablet2 mg/1OralMylan Pharmaceuticals Inc.1999-06-17Not applicableUs
EstradiolTablet2 mg/1OralGolden State Medical Supply, Inc.2016-08-16Not applicableUs
EstradiolTablet1 mg/1OralBlenheim Pharmacal, Inc.2012-02-14Not applicableUs
EstradiolTablet1 mg/1OralAv Pak2014-02-12Not applicableUs
EstradiolTablet1 mg/1OralDIRECT RX2015-01-01Not applicableUs
EstradiolTablet1 mg/1OralRebel Distributors Corp1996-03-14Not applicableUs
EstradiolTablet2 mg/1OralPhysicians Total Care, Inc.2003-05-07Not applicableUs
EstradiolTablet2 mg/1Oralbryant ranch prepack1996-03-14Not applicableUs
EstradiolTablet1 mg/1OralTeva Pharmaceuticals Usa, Inc.1997-10-28Not applicableUs
EstradiolTablet2 mg/1OralNu Care Pharmaceuticals, Inc.1997-10-28Not applicableUs
EstradiolPatch.1 mg/dTransdermalMylan Pharmaceuticals Inc.2000-02-24Not applicableUs
EstradiolTablet1 mg/1OralWatson Laboratories, Inc.1996-03-14Not applicableUs
EstradiolTablet1 mg/1OralPd Rx Pharmaceuticals, Inc.1996-03-14Not applicableUs
EstradiolTablet1 mg/1OralGolden State Medical Supply, Inc.2014-11-26Not applicableUs
EstradiolTablet1 mg/1OralA S Medication Solutions1997-10-28Not applicableUs
EstradiolTablet.5 mg/1OralKAISER FOUNDATION HOSPITALS2015-10-14Not applicableUs
EstradiolTablet1 mg/1OralPreferred Pharmaceuticals, Inc.2012-02-13Not applicableUs
EstradiolTablet2 mg/1OralPd Rx Pharmaceuticals, Inc.2016-08-03Not applicableUs
EstradiolTablet1 mg/1OralProficient Rx LP1997-10-28Not applicableUs
EstradiolTablet2 mg/1OralHeritage Pharmaceuticals Inc2010-11-05Not applicableUs
EstradiolPatch1.94 mg/48[USP'U]TransdermalPhysicians Total Care, Inc.2008-12-11Not applicableUs
EstradiolTablet1 mg/1OralPreferred Pharmaceuticals, Inc.2014-12-04Not applicableUs
Estradiol ValerateInjection, solution20 mg/mLIntramuscularPerrigo Company2010-03-31Not applicableUs
Estradiol ValerateInjection, solution40 mg/mLIntramuscularPerrigo Company2010-03-31Not applicableUs
YuvafemTablet10 ug/1VaginalAmneal Pharmaceuticals, LLC2015-06-07Not applicableUs
YuvafemTablet10 ug/1VaginalAv Kare, Inc.2016-10-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EstradiolPellet25 mg/1OralQualgen Llc2015-09-01Not applicableUs
EstradiolPellet6 mg/1OralQualgen Llc2015-09-01Not applicableUs
EstradiolPellet18 mg/1OralQualgen Llc2015-09-01Not applicableUs
EstradiolPellet10 mg/1OralQualgen Llc2015-09-01Not applicableUs
EstradiolPellet20 mg/1OralQualgen Llc2015-09-01Not applicableUs
EstradiolPellet12.5 mg/1OralQualgen Llc2015-09-01Not applicableUs
EstradiolPellet22 mg/1OralQualgen Llc2015-09-01Not applicableUs
EstradiolPellet15 mg/1OralQualgen Llc2015-09-01Not applicableUs
International Brands
NameCompany
Estraderm MXNovartis
Estraderm TTSNovartis
EstrasorbMedicis
EstrofemNovo Nordisk
FemtraceWarner Chilcott
InnofemNovo Nordisk
VivelleNovartis
Brand mixtures
NameLabellerIngredients
ActivellaNovo Nordisk
ActivelleNovo Nordisk Canada Inc
Activelle LdNovo Nordisk Canada Inc
AmabelzLupin Pharmaceuticals, Inc.
AngeliqBayer Health Care Pharmaceuticals Inc.
Climara ProBayer Health Care Pharmaceuticals Inc.
CombipatchNovartis Pharmaceuticals Corporation
Combipatch (estradiol/norethindrone Acetate Transdermal System)NOVEN THERAPEUTICS, LLC
Estalis 140/50 McgNovartis Pharmaceuticals Canada Inc
Estalis 250/50 McgNovartis Pharmaceuticals Canada Inc
Estalis SequiNovartis Pharmaceuticals Canada Inc
EstracombNovartis Pharmaceuticals Canada Inc
Estradiol / Norethindrone AcetateBreckenridge Pharmaceutical, Inc.
Estrogel PropakMerck Canada Inc
LopreezaAmneal Pharmaceuticals of New York, LLC
MimveyTeva Pharmaceuticals Usa, Inc.
Mimvey LoTeva Pharmaceuticals Usa, Inc.
NataziaBayer Inc
Neo Pause InjectionNeolab Inc
PrefestaSearchlight Pharma Inc
Salts
Name/CASStructureProperties
Estradiol acetate
4245-41-4
Thumb
  • InChI Key: FHXBMXJMKMWVRG-SLHNCBLASA-N
  • Monoisotopic Mass: 314.188194698
  • Average Mass: 314.4186
DBSALT000065
Estradiol benzoate
50-50-0
Thumb
  • InChI Key: UYIFTLBWAOGQBI-BZDYCCQFSA-N
  • Monoisotopic Mass: 376.203844762
  • Average Mass: 376.488
DBSALT000066
Estradiol cypionate
313-06-4
Thumb
  • InChI Key: UOACKFBJUYNSLK-XRKIENNPSA-N
  • Monoisotopic Mass: 396.266445018
  • Average Mass: 396.5622
DBSALT000067
Estradiol hemihydrate
35380-71-3
Thumb
  • InChI Key: ZVVGLAMWAQMPDR-WVEWYJOQSA-N
  • Monoisotopic Mass: 562.36582471
  • Average Mass: 562.791
DBSALT001383
Estradiol valerate
979-32-8
Thumb
  • InChI Key: RSEPBGGWRJCQGY-RBRWEJTLSA-N
  • Monoisotopic Mass: 356.23514489
  • Average Mass: 356.4984
DBSALT000068
Categories
UNII4TI98Z838E
CAS number50-28-2
WeightAverage: 272.382
Monoisotopic: 272.177630012
Chemical FormulaC18H24O2
InChI KeyVOXZDWNPVJITMN-ZBRFXRBCSA-N
InChI
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
IUPAC Name
(1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-triene-5,14-diol
SMILES
[H][C@@]12CC[[email protected]](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Pharmacology
IndicationFor the treatment of urogenital symptoms associated with post-menopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria).
Structured Indications
PharmacodynamicsEstradiol, the principal intracellular human estrogen, is substantially more active than its metabolites, estrone and estriol, at the cellular level.
Mechanism of actionEstradiol enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.
TargetKindPharmacological actionActionsOrganismUniProt ID
Estrogen receptorProteinyes
agonist
HumanP03372 details
Estrogen receptor betaProteinyes
agonist
HumanQ92731 details
Nuclear receptor subfamily 1 group I member 2ProteinunknownNot AvailableHumanO75469 details
Related Articles
Absorption43%
Volume of distributionNot Available
Protein binding>95%
Metabolism

Exogenous estrogens are metabolized using the same mechanism as endogenous estrogens. Estrogens are partially metabolized by cytochrome P450.

SubstrateEnzymesProduct
Estradiol
2-hydroxyestradiolDetails
Estradiol
4-hydroxystradiolDetails
Estradiol
Not Available
Estradiol-17beta 3-sulfateDetails
Estradiol
Not Available
2-Methoxyestrone 3-glucuronideDetails
Estradiol
Not Available
17-beta-Estradiol-3-glucuronideDetails
Estradiol
Not Available
2-Methoxy-estradiol-17b 3-glucuronideDetails
Estradiol
Not Available
17-beta-Estradiol glucuronideDetails
Estradiol
Not Available
3,17-Androstanediol glucuronideDetails
Estradiol
Not Available
17-alpha-Estradiol-3-glucuronideDetails
Estradiol
Not Available
Estradiol-17alpha 3-D-glucuronosideDetails
Estradiol
Not Available
17-beta-estradiol 3-sulfate-17-(beta-D-glucuronide)Details
Estradiol
Not Available
17-Beta-Estradiol-3,17-beta-sulfateDetails
Route of eliminationEstradiol, estrone and estriol are excreted in the urine along with glucuronide and sulfate conjugates.
Half life36 hours
ClearanceNot Available
ToxicityCan cause nausea and vomiting, and withdrawal bleeding may occur in females.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Aromatase deficiencyDiseaseSMP00565
17-Beta Hydroxysteroid Dehydrogenase III DeficiencyDiseaseSMP00356
Androgen and Estrogen MetabolismMetabolicSMP00068
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Estradiol can be decreased when it is combined with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Estradiol.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estradiol.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Estradiol can be decreased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Estradiol can be decreased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Estradiol.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Estradiol.Experimental, Illicit
AbciximabEstradiol may decrease the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Estradiol can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Estradiol.Approved, Investigational
AcenocoumarolEstradiol may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Estradiol can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Estradiol.Withdrawn
AcitretinThe therapeutic efficacy of Estradiol can be decreased when used in combination with Acitretin.Approved
AdapaleneThe therapeutic efficacy of Estradiol can be decreased when used in combination with Adapalene.Approved
AfatinibThe serum concentration of Estradiol can be increased when it is combined with Afatinib.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Estradiol.Experimental
AlbendazoleThe serum concentration of Estradiol can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Estradiol.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Estradiol.Experimental
AlectinibThe serum concentration of Estradiol can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Estradiol can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe therapeutic efficacy of Estradiol can be decreased when used in combination with Alitretinoin.Approved, Investigational
AlogliptinThe serum concentration of Estradiol can be decreased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Estradiol can be decreased when it is combined with Alpha-1-proteinase inhibitor.Approved
AmantadineThe serum concentration of Estradiol can be increased when it is combined with Amantadine.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Estradiol.Experimental
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Estradiol.Approved
Aminohippuric acidThe serum concentration of Estradiol can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Estradiol.Approved
AmiodaroneThe metabolism of Estradiol can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Estradiol can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Estradiol can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe therapeutic efficacy of Estradiol can be decreased when used in combination with Amobarbital.Approved, Illicit
AmprenavirThe serum concentration of Estradiol can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Estradiol can be increased when it is combined with Amsacrine.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.Approved, Investigational
AncrodEstradiol may decrease the anticoagulant activities of Ancrod.Investigational
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Estradiol.Investigational
Anthrax immune globulin humanEstradiol may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Antithrombin III humanThe serum concentration of Estradiol can be decreased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Estradiol can be decreased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Estradiol can be decreased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Estradiol can be decreased when it is combined with Aprotinin.Approved, Withdrawn
ArdeparinEstradiol may decrease the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanThe serum concentration of Estradiol can be decreased when it is combined with Argatroban.Approved, Investigational
ArmodafinilThe serum concentration of Estradiol can be decreased when it is combined with Armodafinil.Approved, Investigational
ArtemetherThe serum concentration of Estradiol can be decreased when it is combined with Artemether.Approved
AstemizoleThe serum concentration of Estradiol can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Estradiol can be decreased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Estradiol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Estradiol can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Estradiol can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Estradiol can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Estradiol can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Estradiol can be increased when it is combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Estradiol.Investigational
BarbexacloneThe therapeutic efficacy of Estradiol can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Estradiol can be decreased when used in combination with Barbital.Illicit
BatimastatThe serum concentration of Estradiol can be decreased when it is combined with Batimastat.Experimental
BecaplerminEstradiol may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe serum concentration of Beclomethasone can be increased when it is combined with Estradiol.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estradiol.Approved, Investigational
BenazeprilThe serum concentration of Estradiol can be decreased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Estradiol can be decreased when it is combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Estradiol can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Estradiol can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Estradiol.Approved, Vet Approved
BexaroteneThe serum concentration of Estradiol can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Estradiol can be decreased when it is combined with Bi201335.Investigational
BiperidenThe serum concentration of Estradiol can be increased when it is combined with Biperiden.Approved
BivalirudinThe serum concentration of Estradiol can be decreased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Estradiol can be decreased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Estradiol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Estradiol can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Estradiol can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Estradiol can be increased when it is combined with Bromocriptine.Approved, Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Estradiol.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Estradiol.Withdrawn
BuprenorphineThe serum concentration of Estradiol can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Estradiol can be increased when it is combined with Buspirone.Approved, Investigational
C1 Esterase Inhibitor (Human)Estradiol may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).Approved
C1 Esterase Inhibitor (Recombinant)Estradiol may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).Approved
CabazitaxelThe serum concentration of Estradiol can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Estradiol can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Estradiol can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Estradiol can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Estradiol can be decreased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Estradiol can be decreased when it is combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Estradiol can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Estradiol can be decreased when it is combined with Captopril.Approved
CarbamazepineThe therapeutic efficacy of Estradiol can be decreased when used in combination with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Estradiol can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Estradiol can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Estradiol.Experimental
CelecoxibCelecoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational
CeritinibThe serum concentration of Estradiol can be increased when it is combined with Ceritinib.Approved
CertoparinEstradiol may decrease the anticoagulant activities of Certoparin.Approved
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Estradiol.Approved
ChloramphenicolThe metabolism of Estradiol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Estradiol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Estradiol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Estradiol can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Estradiol can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Estradiol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Estradiol can be increased when it is combined with Cholesterol.Experimental
CholestyramineThe serum concentration of Estradiol can be decreased when it is combined with Cholestyramine.Approved
Cholic AcidThe serum concentration of Estradiol can be decreased when it is combined with Cholic Acid.Approved
Choline C 11The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Estradiol.Approved
ChymostatinThe serum concentration of Estradiol can be decreased when it is combined with Chymostatin.Experimental
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Estradiol.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Estradiol.Experimental
CilastatinThe serum concentration of Estradiol can be decreased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Estradiol can be decreased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Estradiol can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Estradiol can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Estradiol can be increased when it is combined with Citalopram.Approved
Citric AcidEstradiol may decrease the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Estradiol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Estradiol can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Estradiol can be decreased when it is combined with Clobazam.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Estradiol.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Estradiol.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Estradiol.Approved
ClofazimineThe serum concentration of Estradiol can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Estradiol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClopidogrelThe metabolism of Estradiol can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Estradiol can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Estradiol can be decreased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Estradiol can be increased when it is combined with Colchicine.Approved
ColesevelamThe serum concentration of Estradiol can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Estradiol can be decreased when it is combined with Colestipol.Approved
ColforsinThe serum concentration of Estradiol can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Estradiol can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Estradiol.Approved
CrizotinibThe metabolism of Estradiol can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Estradiol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Estradiol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Estradiol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Estradiol can be decreased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Estradiol can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Estradiol can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Estradiol can be increased when it is combined with Dactinomycin.Approved
DalteparinEstradiol may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidEstradiol may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarunavirThe metabolism of Estradiol can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Estradiol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Estradiol can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Estradiol can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Estradiol.Investigational
DelavirdineThe metabolism of Estradiol can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Estradiol.Investigational
DesipramineThe serum concentration of Estradiol can be increased when it is combined with Desipramine.Approved
DesirudinEstradiol may decrease the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Estradiol can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Estradiol.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Estradiol.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Estradiol.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Estradiol.Vet Approved
DextranEstradiol may decrease the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Estradiol may decrease the anticoagulant activities of Dextran 40.Approved
Dextran 70Estradiol may decrease the anticoagulant activities of Dextran 70.Approved
Dextran 75Estradiol may decrease the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Estradiol can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Estradiol can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolEstradiol may decrease the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Estradiol.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Estradiol.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Estradiol.Approved
DigoxinThe serum concentration of Estradiol can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Estradiol can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Estradiol can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Estradiol can be increased when it is combined with Dipyridamole.Approved
DoxazosinThe serum concentration of Estradiol can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Estradiol can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Estradiol can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Estradiol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Estradiol can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Estradiol can be decreased when combined with Dronedarone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Estradiol.Approved
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Estradiol.Approved
EcabetThe serum concentration of Estradiol can be decreased when it is combined with Ecabet.Approved, Investigational
Edetic AcidEstradiol may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Estradiol can be decreased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Estradiol can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Estradiol can be decreased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Estradiol can be increased when it is combined with Elbasvir.Approved
ElvitegravirThe serum concentration of Estradiol can be decreased when it is combined with Elvitegravir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estradiol.Approved
EnalaprilThe serum concentration of Estradiol can be decreased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Estradiol can be decreased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Estradiol can be decreased when it is combined with Enalkiren.Experimental
EnoxaparinEstradiol may decrease the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Estradiol can be decreased when it is combined with Enzalutamide.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Estradiol.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Estradiol.Approved
ErgonovineThe serum concentration of Estradiol can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Estradiol can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Estradiol can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Estradiol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Estradiol can be decreased when combined with Esomeprazole.Approved, Investigational
EstramustineThe serum concentration of Estradiol can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Estradiol can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Estradiol.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Estradiol.Approved
Ethyl biscoumacetateEstradiol may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
EtoposideThe serum concentration of Estradiol can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational
EtravirineThe serum concentration of Estradiol can be decreased when it is combined with Etravirine.Approved
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Estradiol.Approved, Investigational
ExenatideThe serum concentration of Estradiol can be decreased when it is combined with Exenatide.Approved, Investigational
FelbamateThe serum concentration of Estradiol can be decreased when it is combined with Felbamate.Approved
FelodipineThe serum concentration of Estradiol can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Estradiol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Estradiol can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Estradiol can be increased when it is combined with Fidaxomicin.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Estradiol.Approved
FloxuridineThe metabolism of Estradiol can be decreased when combined with Floxuridine.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Estradiol.Investigational
FluconazoleThe metabolism of Estradiol can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Estradiol.Approved
FluindioneEstradiol may decrease the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Estradiol.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Estradiol.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Estradiol.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Estradiol.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Estradiol.Approved
FluorouracilThe metabolism of Estradiol can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Estradiol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Estradiol can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Estradiol can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Estradiol.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Estradiol.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Estradiol.Approved
FlurazepamThe serum concentration of Estradiol can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Estradiol.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Estradiol.Approved
FluvastatinThe metabolism of Estradiol can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Estradiol can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxEstradiol may decrease the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEstradiol may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Estradiol.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of Estradiol can be decreased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Estradiol can be decreased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Estradiol can be decreased when it is combined with Fosinopril.Approved
FosphenytoinThe therapeutic efficacy of Estradiol can be decreased when used in combination with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Estradiol can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Estradiol can be decreased when it is combined with Gabexate.Investigational
GefitinibThe serum concentration of Estradiol can be increased when it is combined with Gefitinib.Approved, Investigational
GeldanamycinThe serum concentration of Estradiol can be decreased when it is combined with Geldanamycin.Experimental
GemfibrozilThe metabolism of Estradiol can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Estradiol can be increased when it is combined with Genistein.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Estradiol.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Estradiol.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Estradiol.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Estradiol.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Estradiol.Approved
GlyburideThe serum concentration of Estradiol can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Estradiol can be increased when it is combined with Glycerol.Experimental
GM6001The serum concentration of Estradiol can be decreased when it is combined with GM6001.Experimental
Gramicidin DThe serum concentration of Estradiol can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Estradiol can be increased when it is combined with Grepafloxacin.Withdrawn
GriseofulvinThe metabolism of Estradiol can be increased when combined with Griseofulvin.Approved, Vet Approved
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Estradiol.Investigational
HaloperidolThe serum concentration of Estradiol can be increased when it is combined with Haloperidol.Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Estradiol.Investigational
HeparinEstradiol may decrease the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalThe therapeutic efficacy of Estradiol can be decreased when used in combination with Hexobarbital.Approved
HirulogThe serum concentration of Estradiol can be decreased when it is combined with Hirulog.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estradiol.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Estradiol.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Estradiol.Approved, Vet Approved
IdelalisibThe serum concentration of Estradiol can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Estradiol can be decreased when it is combined with idraparinux.Investigational
ImatinibThe metabolism of Estradiol can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Estradiol can be decreased when it is combined with Imidapril.Investigational
ImipramineThe serum concentration of Estradiol can be increased when it is combined with Imipramine.Approved
IndinavirThe metabolism of Estradiol can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Estradiol can be increased when it is combined with Indomethacin.Approved, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Estradiol.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Estradiol.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Estradiol.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Estradiol.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Estradiol.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Estradiol.Approved
IrbesartanThe metabolism of Estradiol can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Estradiol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe serum concentration of Estradiol can be decreased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Estradiol can be decreased when combined with Isoniazid.Approved
IsotretinoinThe therapeutic efficacy of Estradiol can be decreased when used in combination with Isotretinoin.Approved
IsradipineThe metabolism of Estradiol can be decreased when combined with Isradipine.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Estradiol.Investigational
ItraconazoleThe metabolism of Estradiol can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Estradiol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Estradiol can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxazomibThe serum concentration of Estradiol can be decreased when it is combined with Ixazomib.Approved
KetamineThe serum concentration of Estradiol can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Estradiol can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Estradiol.Approved, Investigational
LansoprazoleThe serum concentration of Estradiol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Estradiol can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Estradiol can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideEstradiol may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinThe serum concentration of Estradiol can be decreased when it is combined with Lepirudin.Approved
LevofloxacinThe serum concentration of Estradiol can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Estradiol can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Estradiol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Estradiol can be decreased when it is combined with Linagliptin.Approved
LiothyronineThe serum concentration of Estradiol can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Estradiol can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Estradiol.Approved
LisinoprilThe serum concentration of Estradiol can be decreased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Estradiol can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Estradiol can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Estradiol can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Estradiol can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Estradiol can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Estradiol can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Estradiol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Estradiol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational
MaprotilineThe serum concentration of Estradiol can be increased when it is combined with Maprotiline.Approved
ME-609The serum concentration of ME-609 can be increased when it is combined with Estradiol.Investigational
MebendazoleThe serum concentration of Estradiol can be increased when it is combined with Mebendazole.Approved, Vet Approved
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Estradiol.Approved
MefloquineThe serum concentration of Estradiol can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Estradiol can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Estradiol.Vet Approved
MeprobamateThe serum concentration of Estradiol can be increased when it is combined with Meprobamate.Approved, Illicit
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Estradiol.Approved
MethadoneThe serum concentration of Estradiol can be increased when it is combined with Methadone.Approved
MethohexitalThe therapeutic efficacy of Estradiol can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Estradiol can be decreased when used in combination with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Estradiol.Approved, Vet Approved
MetoprololThe serum concentration of Estradiol can be increased when it is combined with Metoprolol.Approved, Investigational
MetreleptinThe serum concentration of Estradiol can be decreased when it is combined with Metreleptin.Approved
MexiletineThe metabolism of Estradiol can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Estradiol can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Estradiol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Estradiol can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Estradiol can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Estradiol.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Estradiol.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Estradiol.Approved, Investigational
MitomycinThe serum concentration of Estradiol can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Estradiol can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Estradiol can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Estradiol can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Estradiol can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Estradiol can be decreased when it is combined with Moexipril.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Estradiol.Approved, Vet Approved
MorphineThe serum concentration of Estradiol can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolic acidThe serum concentration of Estradiol can be decreased when it is combined with Mycophenolic acid.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Estradiol can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabumetoneNabumetone may increase the thrombogenic activities of Estradiol.Approved
NadroparinEstradiol may decrease the anticoagulant activities of Nadroparin.Approved
NafamostatThe serum concentration of Estradiol can be decreased when it is combined with Nafamostat.Investigational
NafcillinThe metabolism of Estradiol can be increased when combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Estradiol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Estradiol can be increased when it is combined with Naringenin.Experimental
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Estradiol.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Estradiol.Investigational
NCX 4016The serum concentration of Estradiol can be decreased when it is combined with NCX 4016.Investigational
NefazodoneThe metabolism of Estradiol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Estradiol can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Estradiol can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Estradiol can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Estradiol can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Estradiol can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Estradiol can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Estradiol can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Estradiol.Approved
NisoldipineThe serum concentration of Estradiol can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Estradiol can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Estradiol can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe serum concentration of Estradiol can be decreased when it is combined with Nitroaspirin.Investigational
NorethisteroneThe serum concentration of Estradiol can be decreased when it is combined with Norethisterone.Approved
OlaparibThe metabolism of Estradiol can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe serum concentration of Oleoyl estrone can be increased when it is combined with Estradiol.Investigational
OmapatrilatThe serum concentration of Estradiol can be decreased when it is combined with Omapatrilat.Investigational
OmeprazoleThe serum concentration of Estradiol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Estradiol can be increased when it is combined with Osimertinib.Approved
OspemifeneThe risk or severity of adverse effects can be increased when Estradiol is combined with Ospemifene.Approved
OtamixabanThe serum concentration of Estradiol can be decreased when it is combined with Otamixaban.Investigational
OxcarbazepineThe serum concentration of Estradiol can be decreased when it is combined with Oxcarbazepine.Approved
P-NitrophenolThe serum concentration of Estradiol can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Estradiol can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Estradiol can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Estradiol can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Estradiol can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Estradiol.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Estradiol.Approved
ParoxetineThe serum concentration of Estradiol can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Estradiol.Approved
Peginterferon alfa-2bThe serum concentration of Estradiol can be increased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Estradiol can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateEstradiol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe serum concentration of Estradiol can be decreased when it is combined with Perindopril.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Estradiol.Approved, Withdrawn
PhenindioneEstradiol may decrease the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Estradiol can be increased when combined with Phenobarbital.Approved
PhenprocoumonEstradiol may decrease the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe therapeutic efficacy of Estradiol can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Estradiol can be decreased when it is combined with Phosphoramidon.Experimental
PimozideThe serum concentration of Estradiol can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Estradiol.Approved, Investigational
Platelet Activating FactorThe serum concentration of Estradiol can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Estradiol can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Estradiol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Estradiol.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Estradiol.Approved, Nutraceutical
PravastatinThe serum concentration of Estradiol can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Estradiol can be increased when it is combined with Prazosin.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Estradiol.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Estradiol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Estradiol.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Estradiol.Experimental
PrimidoneThe metabolism of Estradiol can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Estradiol can be decreased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Estradiol can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Estradiol can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Estradiol can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Estradiol can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Estradiol can be increased when it is combined with Propranolol.Approved, Investigational
Protein CEstradiol may decrease the anticoagulant activities of Protein C.Approved
Protein S humanEstradiol may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEstradiol may decrease the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Estradiol can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Estradiol can be decreased when it is combined with Prucalopride.Approved
PyrimethamineThe metabolism of Estradiol can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuercetinThe serum concentration of Estradiol can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Estradiol can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Estradiol can be decreased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Estradiol can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Estradiol can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Estradiol can be decreased when combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Estradiol can be decreased when it is combined with Racecadotril.Investigational
RamiprilThe serum concentration of Estradiol can be decreased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Estradiol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Estradiol can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Estradiol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Estradiol can be increased when it is combined with Regorafenib.Approved
RemikirenThe serum concentration of Estradiol can be decreased when it is combined with Remikiren.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Estradiol.Approved, Investigational
ReserpineThe serum concentration of Estradiol can be decreased when it is combined with Reserpine.Approved
ReviparinEstradiol may decrease the anticoagulant activities of Reviparin.Approved
RifabutinThe metabolism of Estradiol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Estradiol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Estradiol can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Estradiol can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Estradiol.Approved
RitonavirThe metabolism of Estradiol can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Estradiol can be decreased when it is combined with Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Estradiol.Investigational, Withdrawn
RolapitantThe serum concentration of Estradiol can be increased when it is combined with Rolapitant.Approved
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Estradiol.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Estradiol.Approved, Investigational
SaquinavirThe metabolism of Estradiol can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Estradiol can be decreased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Estradiol can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Estradiol can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Estradiol can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Estradiol can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Estradiol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Estradiol can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Estradiol can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Estradiol can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Estradiol can be decreased when it is combined with Sitagliptin.Approved, Investigational
Somatropin recombinantThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Estradiol.Approved, Investigational
SorafenibThe serum concentration of Estradiol can be increased when it is combined with Sorafenib.Approved, Investigational
SpiraprilThe serum concentration of Estradiol can be decreased when it is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Estradiol can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Estradiol can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Estradiol can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Estradiol can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Estradiol can be decreased when it is combined with Streptozocin.Approved
SulfadiazineThe metabolism of Estradiol can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Estradiol can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Estradiol can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Estradiol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideEstradiol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Estradiol can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Estradiol can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Estradiol can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Estradiol can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Estradiol can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Estradiol can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Estradiol can be decreased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Estradiol can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Estradiol can be increased when it is combined with Telmisartan.Approved, Investigational
TemocaprilThe serum concentration of Estradiol can be decreased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Estradiol can be increased when it is combined with Temsirolimus.Approved
TenofovirThe metabolism of Estradiol can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Estradiol can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Estradiol can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Estradiol can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Estradiol can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Estradiol can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideEstradiol may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Estradiol can be decreased when combined with Theophylline.Approved
ThiamylalThe therapeutic efficacy of Estradiol can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Estradiol.Investigational
ThiopentalThe therapeutic efficacy of Estradiol can be decreased when used in combination with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Estradiol can be decreased when it is combined with Thiorphan.Experimental
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Estradiol.Approved
TicagrelorThe serum concentration of Estradiol can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Estradiol can be decreased when combined with Ticlopidine.Approved
TipranavirEstradiol may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Estradiol.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Estradiol.Approved
TocilizumabThe serum concentration of Estradiol can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Estradiol.Approved
TolbutamideThe metabolism of Estradiol can be decreased when combined with Tolbutamide.Approved
TolvaptanThe serum concentration of Estradiol can be increased when it is combined with Tolvaptan.Approved
TopiramateThe serum concentration of Estradiol can be decreased when it is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Estradiol.Approved, Investigational
TrandolaprilThe serum concentration of Estradiol can be decreased when it is combined with Trandolapril.Approved
Tranexamic AcidEstradiol may increase the thrombogenic activities of Tranexamic Acid.Approved
TranylcypromineThe metabolism of Estradiol can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe serum concentration of Estradiol can be decreased when it is combined with Trazodone.Approved, Investigational
TretinoinThe therapeutic efficacy of Estradiol can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Estradiol.Approved, Vet Approved
TrifluoperazineThe serum concentration of Estradiol can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Estradiol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Estradiol can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Estradiol can be increased when it is combined with Trimipramine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Estradiol.Withdrawn
TroleandomycinThe serum concentration of Estradiol can be increased when it is combined with Troleandomycin.Approved
UbenimexThe serum concentration of Estradiol can be decreased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Estradiol can be decreased when it is combined with Ulinastatin.Investigational
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Estradiol.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Estradiol.Investigational, Withdrawn
Valproic AcidThe metabolism of Estradiol can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Estradiol can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Estradiol can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Estradiol can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Estradiol can be decreased when combined with Verapamil.Approved
VildagliptinThe serum concentration of Estradiol can be decreased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Estradiol can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Estradiol can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Estradiol can be increased when it is combined with Vinorelbine.Approved, Investigational
Vitamin CThe serum concentration of Estradiol can be increased when it is combined with Vitamin C.Approved, Nutraceutical
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Estradiol.Approved, Investigational
VoriconazoleThe metabolism of Estradiol can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinEstradiol may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Estradiol can be decreased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
Ym150The serum concentration of Estradiol can be decreased when it is combined with Ym150.Investigational
ZafirlukastThe metabolism of Estradiol can be decreased when combined with Zafirlukast.Approved, Investigational
ZimelidineThe serum concentration of Estradiol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Estradiol can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Take with food to decrease nausea.
References
Synthesis Reference

Akira Nakagawa, Munehiko Hirano, Miyuki Shinmura, “Estradiol percutaneous administration preparations.” U.S. Patent US5248676, issued November, 1980.

US5248676
General References
  1. Pentikainen V, Erkkila K, Suomalainen L, Parvinen M, Dunkel L: Estradiol acts as a germ cell survival factor in the human testis in vitro. J Clin Endocrinol Metab. 2000 May;85(5):2057-67. [PubMed:10843196 ]
  2. Sharpe RM, Skakkebaek NE: Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet. 1993 May 29;341(8857):1392-5. [PubMed:8098802 ]
  3. Raman JD, Schlegel PN: Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9. [PubMed:11792932 ]
  4. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER: Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997 Jul 10;337(2):91-5. [PubMed:9211678 ]
  5. Behl C, Widmann M, Trapp T, Holsboer F: 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun. 1995 Nov 13;216(2):473-82. [PubMed:7488136 ]
  6. Schmidt JW, Wollner D, Curcio J, Riedlinger J, Kim LS: Hormone replacement therapy in menopausal women: Past problems and future possibilities. Gynecol Endocrinol. 2006 Oct;22(10):564-77. [PubMed:17135036 ]
  7. Foresta C, Zuccarello D, Biagioli A, De Toni L, Prana E, Nicoletti V, Ambrosini G, Ferlin A: Oestrogen stimulates endothelial progenitor cells via oestrogen receptor-alpha. Clin Endocrinol (Oxf). 2007 Oct;67(4):520-5. Epub 2007 Jun 15. [PubMed:17573901 ]
  8. Garcia-Segura LM, Sanz A, Mendez P: Cross-talk between IGF-I and estradiol in the brain: focus on neuroprotection. Neuroendocrinology. 2006;84(4):275-9. Epub 2006 Nov 23. [PubMed:17124377 ]
External Links
ATC CodesG03FA12G03FA17G03FA11G03FA16G03FB12G03FB01G03AB08G03FA08G03EA03G03FB09G03FA05G03EA02G03AA14G03FA14G03FB05G03FB11G03CA53G03HB01G03FA07G03FB04G03FB07G03FA09G03FA13G03FA06G03EA01G03FB10G03FA15G03CA03G03FB02G03FA01G03FB06G02BB01G03FA03G03FB08G03FA10G03FA04G03FB03G03FA02
AHFS Codes
  • 68:16.04
PDB EntriesNot Available
FDA labelDownload (89.1 KB)
MSDSDownload (73.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8917
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7058
P-glycoprotein inhibitor INon-inhibitor0.9147
P-glycoprotein inhibitor IINon-inhibitor0.9403
Renal organic cation transporterNon-inhibitor0.8008
CYP450 2C9 substrateNon-substrate0.727
CYP450 2D6 substrateNon-substrate0.801
CYP450 3A4 substrateSubstrate0.7132
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.939
CYP450 2D6 inhibitorNon-inhibitor0.9574
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7887
Ames testNon AMES toxic0.9198
CarcinogenicityNon-carcinogens0.8829
BiodegradationNot ready biodegradable0.9746
Rat acute toxicity2.2272 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8647
hERG inhibition (predictor II)Inhibitor0.6624
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Warner chilcott inc
  • Watson laboratories inc
  • Bayer healthcare pharmaceuticals inc
  • Women first healthcare inc
  • Novartis pharmaceuticals corp
  • Mylan technologies inc
  • Ortho mcneil pharmaceutical inc
  • Parke davis pharmaceutical research div warner lambert co
  • Azur pharma international ii ltd
  • Ascend therapeutics inc
  • Upsher smith laboratories inc
  • Pharmacia and upjohn co
  • Kv pharmaceutical co
  • Bristol myers squibb co
  • Bristol myers squibb co pharmaceutical research institute
  • Aai pharma inc
  • Barr laboratories inc
  • Heritage pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Usl pharma inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Novo nordisk inc
  • Galen ltd
  • Graceway pharmaceuticals llc
  • Jhp pharmaceuticals llc
  • Pharmaforce inc
  • Sandoz canada inc
  • Private formulations inc
  • Monarch pharmaceuticals inc
  • Wyeth ayerst laboratories
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral
TabletOral
PatchTransdermal7.6 mg
PatchTransdermal2 mg
PatchTransdermal3.8 mg
PatchTransdermal5.7 mg
PatchTransdermal
Patch, extended releaseTransdermal
InjectionIntramuscular10 mg/mL
InjectionIntramuscular20 mg/mL
InjectionIntramuscular40 mg/mL
LiquidIntramuscular10 mg
InjectionIntramuscular5 mg/mL
GelTopical.25 mg/g
GelTopical.5 mg/g
GelTopical1 mg/g
GelTransdermal0.1 %
GelTransdermal.6 mg/g
Gel, meteredTopical.52 mg/g
CreamVaginal.1 mg/g
TabletOral0.5 mg
TabletOral1 mg
TabletOral2 mg
Patch, extended releaseTransdermal8 mg
Patch, extended releaseTransdermal2 mg
Patch, extended releaseTransdermal4 mg
PatchTransdermal.025 mg/d
PatchTransdermal.0375 mg/d
PatchTransdermal.05 mg/d
PatchTransdermal.06 mg/d
PatchTransdermal.075 mg/d
PatchTransdermal.1 mg/d
PatchTransdermal.97 mg/48[USP'U]
PatchTransdermal1.46 mg/48[USP'U]
PatchTransdermal1.94 mg/48[USP'U]
Patch, extended releaseTransdermal.025 mg/d
Patch, extended releaseTransdermal.0375 mg/d
Patch, extended releaseTransdermal.05 mg/d
Patch, extended releaseTransdermal.075 mg/d
Patch, extended releaseTransdermal.1 mg/d
PelletOral10 mg/1
PelletOral12.5 mg/1
PelletOral15 mg/1
PelletOral18 mg/1
PelletOral20 mg/1
PelletOral22 mg/1
PelletOral25 mg/1
PelletOral6 mg/1
TabletOral.5 mg/1
TabletOral1 mg/1
TabletOral2 mg/1
Injection, solutionIntramuscular20 mg/mL
Injection, solutionIntramuscular40 mg/mL
PatchTransdermal1.56 mg
PatchTransdermal0.39 mg
PatchTransdermal0.585 mg
PatchTransdermal0.780 mg
PatchTransdermal1.17 mg
RingVaginal2 mg/1
RingVaginal2 mg
GelTransdermal0.06 %
Gel, meteredTransdermal.75 mg/1.25g
Capsule; gel, meteredOral; Transdermal
SprayTransdermal1.53 mg/1
Spray, meteredTransdermal1.53 mg/1
RingVaginal.05 mg/d
RingVaginal.1 mg/d
RingVaginal.1 mg/24[USP'U]
PatchTransdermal14 ug/d
Film, extended releaseTransdermal.025 mg/d
Film, extended releaseTransdermal.0375 mg/d
Film, extended releaseTransdermal.05 mg/d
Film, extended releaseTransdermal.075 mg/d
Film, extended releaseTransdermal.1 mg/d
SolutionIntramuscular
LiquidIntramuscular20 mg
PatchTransdermal10 mg
PatchTransdermal15 mg
PatchTransdermal20 mg
PatchTransdermal5 mg
PatchTransdermal7.5 mg
PatchTransdermal8 mg
PatchTransdermal4 mg
PatchTransdermal6 mg
InsertVaginal10 ug/1
TabletVaginal25 mcg
Tablet, film coatedVaginal10 ug/1
TabletVaginal10 mcg
PatchTransdermal8.66 mg
PatchTransdermal3.28 mg
PatchTransdermal4.33 mg
PatchTransdermal6.56 mg
TabletVaginal10 ug/1
Prices
Unit descriptionCostUnit
Femring 0.1 mg/24hr Ring218.6USD ring
Estring 2 mg Ring Box210.39USD box
Femring 0.10 mg vaginal ring210.19USD ring
Femring 0.05 mg/24hr Ring205.15USD ring
Estring 2 mg vaginal ring202.3USD ring
Femring 0.05 mg vaginal ring197.26USD ring
Elestrin 0.52 mg/0.87 gm(0.06%) Gel 144 gm Bottle162.06USD bottle
Ethinyl estradiol powder140.0USD g
Vagifem 18 25 mcg tablet Box139.78USD box
Estrace 0.1 mg/gm Cream 42.5 gm Tube133.27USD tube
Estradiol cypionate powder88.74USD g
Delestrogen 10 mg/ml Oil 5ml Vial88.04USD vial
Evamist 1.53 mg/spray Solution 8.1ml Bottle87.18USD bottle
Divigel 1 mg/gm Gel Box Of 30 gm85.53USD box
Estrogel 0.75 mg/1.25 gm(0.06%) Gel 50 gm Bottle84.24USD bottle
Divigel 30 0.25 mg/0.25 gm Gel 30 Patches/box81.24USD box
Climara 4 0.025 mg/24hr Patches Box75.58USD box
Climara 4 0.05 mg/24hr Patches Box75.58USD box
Climara 4 0.1 mg/24hr Patches Box75.58USD box
Menostar 4 14 mcg/24hr Patches Box73.18USD box
Divigel 0.5 mg/0.5 gm Gel Box72.99USD box
Estraderm 8 0.1 mg/24hr Patches Box72.47USD box
Vivelle-Dot 8 0.1 mg/24hr Patches Box72.46USD box
Vivelle-Dot 8 0.025 mg/24hr Patches Box70.69USD box
Climara 4 0.075 mg/24hr Patches Box69.04USD box
Climara Pro 4 0.045-0.015 mg/day Patches Box69.04USD box
Vivelle-Dot 8 0.0375 mg/24hr Patches Box68.84USD box
Vivelle-Dot 8 0.075 mg/24hr Patches Box66.89USD box
CombiPatch 8 0.05-0.25 mg/day Patches Box66.45USD box
Estraderm 8 0.05 mg/24hr Patches Box66.35USD box
Vivelle-Dot 8 0.05 mg/24hr Patches Box65.99USD box
Estring 2 mg Slow-Release Ring65.39USD ring
Alora 8 0.1 mg/24hr Patches Box62.99USD box
Alora 8 0.05 mg/24hr Patches Box60.99USD box
Alora 8 0.075 mg/24hr Patches Box58.27USD box
Vagifem 8 25 mcg tablet Box58.23USD box
Vagifem 8 10 mcg tablet Box54.99USD box
Vivelle 8 0.05 mg/24hr Patches Box49.99USD box
Estradiol benzoate powder42.0USD g
Estradiol 4 0.025 mg/24hr Patches Box40.92USD box
Estradiol 4 0.05 mg/24hr Patches Box40.92USD box
Estradiol 4 0.075 mg/24hr Patches Box40.92USD box
Estradiol 4 0.1 mg/24hr Patches Box40.92USD box
Estradiol 4 0.06 mg/24hr Patches Box39.99USD box
Delestrogen 40 mg/ml Oil39.52USD ml
Estradiol 4 0.0375 mg/24hr Patches Box39.35USD box
Delestrogen 40 mg/ml vial38.0USD ml
Estradiol valerate 40 mg/ml vial35.62USD ml
Estradiol valerate powder32.13USD g
Delestrogen 20 mg/ml Oil23.82USD ml
Delestrogen 20 mg/ml vial22.91USD ml
Estradiol valerate 20 mg/ml vial21.25USD ml
Estradiol 0.1 mg/day patch20.55USD patch
Estradiol powder17.86USD g
Climara 0.0375 mg/24hr Patches17.26USD patch
Climara 0.06 mg/24hr Patches17.26USD patch
Estradiol 0.05 mg/day patch16.91USD patch
Delestrogen 10 mg/ml vial16.25USD ml
Climara 0.025 mg/day patch15.77USD patch
Climara 0.0375 mg/day patch15.77USD patch
Climara 0.05 mg/day patch15.77USD patch
Climara 0.06/mg day patch15.77USD patch
Climara 0.075 mg/day patch15.77USD patch
Climara 0.1 mg/day patch15.77USD patch
Climara pro patch15.77USD patch
Estradiol valerate 10 mg/ml vial15.24USD ml
Evamist 1.53 mg/spray10.43USD ml
Estradiol tds 0.025 mg/day9.84USD each
Estradiol tds 0.0375 mg/day9.84USD each
Estradiol tds 0.06 mg/day9.84USD each
Estradiol tds 0.075 mg/day9.84USD each
Depo-Estradiol 5 mg/ml Oil9.66USD ml
Estraderm 0.1 mg patch8.66USD patch
CombiPatch 0.05-0.14 mg/day Patches8.65USD patch
Vivelle-dot 0.075 mg patch8.49USD patch
Estraderm 0.05 mg patch8.07USD patch
Combipatch 0.05-0.14 mg ptch7.92USD patch
Combipatch 0.05-0.25 mg ptch7.91USD patch
Depo-estradiol 5 mg/ml vial7.89USD ml
Vivelle-dot 0.1 mg patch7.89USD patch
Vivelle-dot 0.05 mg patch7.61USD patch
Vivelle-dot 0.0375 mg patch7.54USD patch
Vivelle-dot 0.025 mg patch7.53USD patch
Alora 0.1 mg patch7.16USD patch
Alora 0.075 mg patch7.0USD patch
Alora 0.05 mg patch6.86USD patch
Vagifem 10 mcg vaginal tab6.78USD each
Vagifem 25 mcg vaginal tab6.78USD each
Climara 100 (7.8 Mg/Pth) 100 mcg/day Patch6.67USD patch
Climara 75 (5.7 Mg/Pth) 75 mcg/day Patch6.31USD patch
Alora 0.025 mg patch6.26USD patch
Vivelle 0.1 mg patch5.94USD patch
Climara 50 (3.9 Mg/Pth) 50 mcg/day Patch5.91USD patch
Vivelle 0.05 mg patch5.74USD patch
Climara 25 (2 Mg/Pth) 25 mcg/day Patch5.54USD patch
Estraderm-100 (8.0 Mg/Pth) 100 mcg/day Patch4.52USD patch
Estraderm-25 (2 Mg/Pth) 25 mcg/day Patch3.74USD patch
Estradot 100 (1.56 Mg/Pth) 100 mcg/day Patch3.49USD patch
Estradot 75 (1.17 Mg/Pth) 75 mcg/day Patch3.3USD patch
Vagifem 25 mcg Tablet3.21USD tablet
Estradot 50 (0.78 Mg/Pth) 50 mcg/day Patch3.07USD patch
Oesclim 50 (10 Mg/Pth) 50 mcg/day Patch3.06USD patch
Estrace 0.01% cream3.05USD g
Estrace 2 mg tablet2.98USD tablet
Estradot 37.5 (0.585 Mg/Pth) 37.5 mcg/day Patch2.88USD patch
Estradot 25 (0.39 Mg/Pth) 25 mcg/day Patch2.86USD patch
Estrasorb 4.35 mg/1.74 gm Emulsion 1.74 gm Packet2.83USD packet
Oesclim 25 (5 Mg/Pth) 25 mcg/day Patch2.83USD patch
Divigel 0.25 mg gel packet2.74USD each
Divigel 0.5 mg gel packet2.74USD each
Divigel 1 mg gel packet2.74USD g
Sandoz Estradiol Derm 100 (8 Mg/Pth) 100 mcg/day Patch2.64USD patch
Menest 2.5 mg tablet2.6USD tablet
Femtrace 1.8 mg tablet2.59USD tablet
Sandoz Estradiol Derm 75 (6 Mg/Pth) 75 mcg/day Patch2.5USD patch
Sandoz Estradiol Derm 50 (4 Mg/Pth) 50 mcg/day Patch2.34USD patch
Estrace 0.5 mg tablet2.29USD tablet
Femtrace 0.45 mg tablet2.02USD tablet
Femtrace 0.9 mg tablet2.02USD tablet
Estrace 1 mg tablet1.93USD tablet
Estrogel 0.06% gel1.63USD g
Menest 1.25 mg tablet1.56USD tablet
Menest 0.625 mg tablet1.41USD tablet
Estrasorb packet1.21USD g
Elestrin 0.06% gel0.94USD g
Menest 0.3 mg tablet0.89USD tablet
Gynodiol 1.5 mg tablet0.5USD tablet
Estradiol 2 mg tablet0.49USD tablet
Estrace 2 mg Tablet0.44USD tablet
Estradiol 1 mg tablet0.42USD tablet
Estradiol 0.5 mg tablet0.36USD tablet
Estrogel 0.06 % Gel0.31USD g
Estrace 1 mg Tablet0.25USD tablet
Estrace 0.5 mg Tablet0.13USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1338660 No1996-10-222013-10-22Canada
CA2306881 No2008-09-022018-11-19Canada
US5223261 No1993-06-292010-06-29Us
US5855906 No1995-12-192015-12-19Us
US5860946 No1997-07-012017-07-01Us
US5891868 No1997-11-212017-11-21Us
US6133251 No1996-10-252016-10-25Us
US6299900 No1997-02-192017-02-19Us
US6692763 No1997-11-212017-11-21Us
US6747019 No2000-03-202020-03-20Us
US6818226 No1997-02-192017-02-19Us
US6841716 No2000-04-272020-04-27Us
US6884793 No1996-10-252016-10-25Us
US6923983 No1997-02-192017-02-19Us
US6933395 No1997-08-112017-08-11Us
US6962908 No2001-12-212021-12-21Us
US6978945 No2002-07-312022-07-31Us
US7018992 No2002-09-172022-09-17Us
US7198801 No2002-06-252022-06-25Us
US7320970 No2000-03-302020-03-30Us
US7470433 No2001-08-032021-08-03Us
US7572779 No2005-10-022025-10-02Us
US7799771 No2001-12-212021-12-21Us
US8071577 No2006-05-132026-05-13Us
US8153616 No2008-01-302028-01-30Us
US8231906 No2010-07-042030-07-04Us
US8906890 No2011-10-222031-10-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point151-152Ott, A.C.; US. Patent 2.61 1,773; September 23,1952; assigned to The Upjohn Company.
water solubility3.6 mg/L (at 27 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.01HANSCH,C ET AL. (1995)
Caco2 permeability-4.77ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0213 mg/mLALOGPS
logP3.57ALOGPS
logP3.75ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)10.33ChemAxon
pKa (Strongest Basic)-0.88ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area40.46 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.9 m3·mol-1ChemAxon
Polarizability32.13 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.34 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (2 TMS)splash10-017r-1791100000-7b16254894cdcb8ee86dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-05fr-0590000000-1dd83cbcb3d21edfbdbdView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-0a4i-2900000000-f3279d6cdab9cf3800fdView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-0a4i-8900000000-0efe28378f612aab8c3dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (JEOL JMS-01-SG-2) , Positivesplash10-00di-1980000000-b2dec84718861de189ecView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI RMU-6E) , Positivesplash10-00di-3940000000-f3692a81f624f15d3e0bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-52) , Positivesplash10-00di-0960000000-be4e96105398cb805cd9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-80) , Positivesplash10-00di-0790000000-5c83456da6e28375ad51View in MoNA
MSMass Spectrum (Electron Ionization)splash10-075a-2920000000-10218bfa5b56f829853eView in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassEstrane steroids
Direct ParentEstrogens and derivatives
Alternative Parents
Substituents
  • Estrogen-skeleton
  • 17-hydroxysteroid
  • Hydroxysteroid
  • 3-hydroxysteroid
  • Phenanthrene
  • Tetralin
  • Benzenoid
  • Cyclic alcohol
  • Secondary alcohol
  • Hydrocarbon derivative
  • Organooxygen compound
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Brama M, Gnessi L, Basciani S, Cerulli N, Politi L, Spera G, Mariani S, Cherubini S, Scotto d'Abusco A, Scandurra R, Migliaccio S: Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):102-8. Epub 2006 Nov 27. [PubMed:17125913 ]
  2. Lehnes K, Winder AD, Alfonso C, Kasid N, Simoneaux M, Summe H, Morgan E, Iann MC, Duncan J, Eagan M, Tavaluc R, Evans CH Jr, Russell R, Wang A, Hu F, Stoica A: The effect of estradiol on in vivo tumorigenesis is modulated by the human epidermal growth factor receptor 2/phosphatidylinositol 3-kinase/Akt1 pathway. Endocrinology. 2007 Mar;148(3):1171-80. Epub 2006 Nov 30. [PubMed:17138652 ]
  3. Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69. [PubMed:2011412 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560). Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA-binding by...
Gene Name:
ESR2
Uniprot ID:
Q92731
Molecular Weight:
59215.765 Da
References
  1. Vijayanathan V, Greenfield NJ, Thomas TJ, Ivanova MM, Tyulmenkov VV, Klinge CM, Gallo MA, Thomas T: Effects of estradiol and 4-hydroxytamoxifen on the conformation, thermal stability, and DNA recognition of estrogen receptor beta. Biochem Cell Biol. 2007 Feb;85(1):1-10. [PubMed:17464340 ]
  2. Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69. [PubMed:2011412 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and is...
Gene Name:
NR1I2
Uniprot ID:
O75469
Molecular Weight:
49761.245 Da
References
  1. Xue Y, Moore LB, Orans J, Peng L, Bencharit S, Kliewer SA, Redinbo MR: Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol. 2007 May;21(5):1028-38. Epub 2007 Feb 27. [PubMed:17327420 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. [PubMed:12865317 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. [PubMed:12865317 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Hanioka N, Tanabe N, Jinno H, Tanaka-Kagawa T, Nagaoka K, Naito S, Koeda A, Narimatsu S: Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8. doi: 10.1016/j.lfs.2010.07.001. Epub 2010 Jul 8. [PubMed:20620155 ]
  2. Guillemette C, Belanger A, Lepine J: Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Res. 2004;6(6):246-54. Epub 2004 Sep 27. [PubMed:15535854 ]
  3. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Androgen binding
Specific Function:
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.
Gene Name:
SHBG
Uniprot ID:
P04278
Molecular Weight:
43778.755 Da
References
  1. Campusano M C, Brusco G F, Campino J C, Rodriguez P L, Arteaga U E: [Assessment of androgenic decline in the elderly]. Rev Med Chil. 2006 Sep;134(9):1123-8. Epub 2006 Dec 12. [PubMed:17171213 ]
  2. Kuba R, Pohanka M, Zakopcan J, Novotna I, Rektor I: Sexual dysfunctions and blood hormonal profile in men with focal epilepsy. Epilepsia. 2006 Dec;47(12):2135-40. [PubMed:17201714 ]
  3. Bendlova B, Zavadilova J, Vankova M, Vejrazkova D, Lukasova P, Vcelak J, Hill M, Cibula D, Vondra K, Starka L, Vrbikova J: Role of D327N sex hormone-binding globulin gene polymorphism in the pathogenesis of polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2007 Apr;104(1-2):68-74. Epub 2007 Jan 26. [PubMed:17258903 ]
  4. Sablik Z, Samborska-Sablik A, Bolinska-Soltysiak H, Goch JH, Kula K: [Hyperandrogenism as a risk factor of coronary artery disease in young women]. Pol Arch Med Wewn. 2006 Feb;115(2):118-24. [PubMed:17274467 ]
  5. Mohamad MJ, Mohammad MA, Karayyem M, Hairi A, Hader AA: Serum levels of sex hormones in men with acute myocardial infarction. Neuro Endocrinol Lett. 2007 Apr;28(2):182-6. [PubMed:17435665 ]
  6. O'Connell MB: Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol. 1995 Sep;35(9 Suppl):18S-24S. [PubMed:8530713 ]
  7. Pardridge WM: Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab. 1986 May;15(2):259-78. [PubMed:3521955 ]
Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. O'Connell MB: Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol. 1995 Sep;35(9 Suppl):18S-24S. [PubMed:8530713 ]
Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Transporter activity
Specific Function:
FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. FABP2 is probably involved in triglyceride-rich lipoprotein synthesis. Binds saturated long-chain fatty acids with a high affinity, but binds with a lower affinity to unsaturated long-chain fatty acids. FABP2 may also help maintain energy homeostasis by functioning as a lipid sensor.
Gene Name:
FABP2
Uniprot ID:
P12104
Molecular Weight:
15207.165 Da
References
  1. Rowland A, Knights KM, Mackenzie PI, Miners JO: Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. Drug Metab Dispos. 2009 Jul;37(7):1395-403. doi: 10.1124/dmd.109.027656. Epub 2009 Apr 27. [PubMed:19398502 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A: Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9. [PubMed:11683238 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Kanai N, Lu R, Bao Y, Wolkoff AW, Vore M, Schuster VL: Estradiol 17 beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter. Am J Physiol. 1996 Feb;270(2 Pt 2):F326-31. [PubMed:8779894 ]
  2. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
  3. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. [PubMed:12920197 ]
  2. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res. 2002 Mar;93(3):231-5. [PubMed:11927002 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A: Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9. [PubMed:11683238 ]
  2. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Rao US, Fine RL, Scarborough GA: Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92. [PubMed:7914405 ]
  2. Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. [PubMed:15290871 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:
SLCO1C1
Uniprot ID:
Q9NYB5
Molecular Weight:
78695.625 Da
References
  1. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. [PubMed:12351693 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as the thyroid hormones T3 (triiodo-L-thyronine), T4 (thyroxine) and rT3, and of estrone-3-sulfate and taurocholate.
Gene Name:
SLCO4A1
Uniprot ID:
Q96BD0
Molecular Weight:
77192.505 Da
References
  1. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60. [PubMed:10873595 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:40